Metabolic & Weight ManagementIn StockMetabolic & Weight Management
Tirzepatide
Also known as: Dual GIP/GLP-1 receptor agonist, LY3298176; parent drug: Mounjaro, Zepbound
Synthetic 39-amino-acid dual GIP and GLP-1 receptor co-agonist; parent compound is an FDA-approved pharmaceutical.
Tirzepatide is a 39-amino-acid synthetic peptide designed as a first-in-class dual agonist at both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the GLP-1 receptor.
It incorporates a C20 fatty diacid side chain attached to position 20 for extended pharmacokinetics through albumin binding.The parent pharmaceutical, marketed by Eli Lilly as Mounjaro (type 2 diabetes) and Zepbound (chronic weight management), was FDA-approved in 2022 and 2023 respectively.
Clinical trial data (SURPASS series, SURMOUNT series) established its pharmacological profile in these indications.
This catalog entry refers to research-grade material for in-vitro laboratory investigation only.In preclinical and in-vitro research, Tirzepatide is studied for its dual-receptor activation profile, biased-agonism properties, comparative pharmacology with pure GLP-1 agonists, and its broader implications for incretin-receptor drug design.
Research applications
- Dual GIP/GLP-1 receptor pharmacology
- Biased-agonism and receptor-signaling research
- Comparative metabolic-peptide pharmacology
- Insulin-secretion and glycemic-regulation models
- Incretin-receptor structural biology
Technical profile
- Net content
- 5 mg
- Molecular formula
- C225H348F2N48O68
- Molecular weight
- 4813.45 g/mol
- CAS
- 2023788-19-2
- Sequence
- YXEGTFTSDYSIYLDKQAAXEFVQWLIAGGPSSGAPPPS (Aib at positions 2 and 13; position 20 modified with γGlu-2×OEG-C20 fatty diacid)
For research use only. Not for human or veterinary consumption. Not intended to diagnose, treat, cure, or prevent any disease. Catalog availability restricted to verified licensed practitioners.
Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist. This 5mg formulation is used in research on dual-incretin pathways for glycemic control and weight management.
